Abstract 12P
Background
Mobile health apps are increasingly gaining attention as opportunities to obtain patient-generated health data without asking for self-report or visiting hospital. Since there are few studies regarding the mobile-based activity trackers in breast cancer patients, we decided to evaluate the feasibility of a mobile walking app and a smart band as a tool for collecting physical activity of breast cancer patients.
Methods
Between June 2017 and March 2018, patients who received surgery for breast cancer at Asan Medical Center were enrolled and asked to access two mobile apps on a weekly basis during a six-month period to automatically record their daily physical activity. Compliance rates of the daily collection via a smartphone walking app and a wearable smart band were compared in a within-subject manner. Longitudinal daily collection rates were calculated to examine a drop-out pattern. Finally, we examined factors associated with the compliance of daily collections using multivariate linear regression analysis.
Results
A total of 160 participants were analyzed, and they are asked to follow an instruction to access the apps at least once a week via their smartphones. Despite the fact that both smartphone app and the smart band showed more than 50% of compliance rate during the six-month follow-up period, smartphone walking app demonstrated higher overall compliance rate (88%) than a smart band (52%). The median value of individual compliance rate is 91% for the walking app and 55% for a smart band. Women having other diseases, an anti-hormonal therapy or a targeted therapy show a higher compliance rate to smartphone walking app, and young women show a higher rate to the app than older women. However, there was no association between any of the patient characteristics and a compliance rate to the smart band.
Conclusions
Smartphone apps or smart bands are feasible tools to collect daily physical activity data for in breast cancer survivors.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Yungil Shin.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
16P - Risk factors and prognostic value of non-alcoholic fatty liver disease (NAFLD) in hormone positive, non-metastatic breast cancer receiving adjuvant hormonal therapy
Presenter: Kartika Taroeno Hariadi
Session: Poster display session
Resources:
Abstract
17P - Distance related outcome in indigenous and non-indigenous breast cancer women of Western Australia
Presenter: Azim Khan
Session: Poster display session
Resources:
Abstract
18P - Usefulness of neutrophil to lymphocyte ratio in early stage breast cancer as predictor of disease-free survival in a Babylon Oncology Center
Presenter: Yaala Raof Al-Bairmany
Session: Poster display session
Resources:
Abstract
19P - Silymarin functionalized quantum cores as selective inhibitor of polo-like kinase 1, and preclinical antitumor activity in human breast cancer xenografts
Presenter: Manickam Paulpandi
Session: Poster display session
Resources:
Abstract
20P - Diagnostic value of serum HER-2 level in compression with tissue HER-2 in breast cancer: A systematic review and meta-analysis
Presenter: Amir Shamshirian
Session: Poster display session
Resources:
Abstract
21P - Clinical outcome of treatment without trastuzumab in HER2 positive breast cancer patients
Presenter: Than Than Aye
Session: Poster display session
Resources:
Abstract
22P - Clinical outcomes after skin-sparing or nipple areolar complex-sparing mastectomy with sentinel lymph node biopsy in early breast cancer patients
Presenter: Hye Yoon Lee
Session: Poster display session
Resources:
Abstract
23P - The correlations between knowledge and attitudes of productive age women toward “SADARI” (breast self-assessment) as early detection of breast cancer in Pejeng Kaja Village, Ubud, Bali
Presenter: Yorky Brahmantya
Session: Poster display session
Resources:
Abstract
24TiP - KEYNOTE-756: A randomized, double-blind, phase III study of pembrolizumab or placebo with neoadjuvant chemotherapy and adjuvant endocrine therapy for high-risk, early-stage, ER+/HER2−breast cancer
Presenter: Fatima Cardoso
Session: Poster display session
Resources:
Abstract
27P - The prognostic value of neutrophil to lymphocyte ratio (NLR) and 18F-FDG PET SUV in breast cancer patients underwent neoadjuvant chemotherapy
Presenter: Soong June Bae
Session: Poster display session
Resources:
Abstract